Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CSCC

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for bullous pemphigoid

Around 27,000 adults in the US are living with uncontrolled cases of the chronic skin disease

- PMLiVE

BioNTech expands mRNA capabilities with $1.25bn CureVac acquisition

The deal will support the advancement of BioNTech’s mRNA-based cancer immunotherapies

- PMLiVE

Sanofi/Regeneron share results for Dupixent in atopic dermatitis patients with darker skin tones

These are the first clinical study results for the drug in a large population of patients with darker skin tones

- PMLiVE

Sanofi to expand immunology capabilities with $9.5bn Blueprint acquisition

The deal will grant Sanofi access to a drug approved for the rare immunologic disorder systemic mastocytosis

- PMLiVE

Sanofi and Stagecoach Performing Arts partner to highlight impact of autoimmune type 1 diabetes

Four adolescents with the condition have formed a girl band and released a song to empower patients

- PMLiVE

Sanofi gains access to Alzheimer’s candidate through $470m Vigil acquisition

A phase 2 trial of the drug is expected to launch in the third quarter of this year

- PMLiVE

Sanofi unveils $20bn US investment to boost R&D and manufacturing presence

The company is the latest major drugmaker to announce a significant investment in the country

regeneron headquarters

Regeneron’s bispecific antibody Lynozyfic approved by EC to treat multiple myeloma

More than 35,000 new cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

Sanofi/Regeneron’s Dupixent granted FDA approval for chronic spontaneous urticaria

More than 300,000 people in the US are living with uncontrolled cases of the inflammatory skin disease

- PMLiVE

Sanofi’s tolebrutinib shown to delay MS disability progression in phase 3 study

The BTK inhibitor has been granted FDA priority review to treat the neurodegenerative disease

- PMLiVE

Sanofi’s Qfitlia granted FDA approval to treat haemophilia A or B

Qfitlia is now the first therapy in the US to treat the rare bleeding disorder regardless of inhibitor status

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links